Evan Cannon

Evan Cannon is currently an analyst at Osage Venture Partners. Prior to this, they worked as a Decision Analytics Associate at ZS from July 2020 to July 2021. Evan also interned at Amicus Therapeutics from July 2019 to June 2020, where they performed a global commercial opportunity assessment for a novel treatment for Pompe Disease, a rare lysosomal storage disorder. Additionally, Evan interned at Fort Wayne Metals from May 2018 to August 2018, where they researched and proposed a change to manufacturing processes to improve the fatigue life of materials with an expected impact on future design considerations. Evan also improved existing product testing technique, evaluated test results, and conditioned and analyzed data to provide process guidance for next generation smart guidewire production. Evan presented the results of complex engineering studies to c-suite executives in an understandable and concise manner. Prior to their work at Free Feet Medical, Evan was the Chief Technical Officer from September 2016 to August 2018.

Evan Cannon has an educational background in both engineering and entrepreneurship. Evan has a Masters in Science from the University of Notre Dame in Engineering, Science, and Technology Entrepreneurship. Evan also has a Bachelor of Engineering from National University of Ireland, Galway in Biomedical Engineering with First Class Honors. Additionally, they participated in a study abroad program in Biomedical Engineering at Purdue University.